4//SEC Filing
AFEYAN NOUBAR 4
Accession 0000899243-23-013992
CIK 0001770121other
Filed
May 25, 8:00 PM ET
Accepted
May 26, 8:00 PM ET
Size
23.4 KB
Accession
0000899243-23-013992
Insider Transaction Report
Form 4
Flagship Ventures Fund V, L.P.
10% Owner
Transactions
- Sale
Common Stock
2023-05-24$6.57/sh−308,290$2,023,986→ 11,276,909 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−13,127$83,385→ 1,434,664 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−9,330$58,093→ 1,425,334 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−102,245$649,481→ 11,174,664 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-24$6.57/sh−39,580$259,851→ 1,447,791 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−72,670$452,480→ 11,101,994 total(indirect: By Flagship Ventures Fund V, L.P.)
Holdings
- 11,441,326(indirect: By LLC)
Common Stock
- 9,725,122(indirect: By Flagship Pioneering Fund VI, L.P.)
Common Stock
Flagship V VentureLabs Rx Fund, L.P.
10% Owner
Transactions
- Sale
Common Stock
2023-05-25$6.35/sh−13,127$83,385→ 1,434,664 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−9,330$58,093→ 1,425,334 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−72,670$452,480→ 11,101,994 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-24$6.57/sh−308,290$2,023,986→ 11,276,909 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-24$6.57/sh−39,580$259,851→ 1,447,791 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−102,245$649,481→ 11,174,664 total(indirect: By Flagship Ventures Fund V, L.P.)
Holdings
- 11,441,326(indirect: By LLC)
Common Stock
- 9,725,122(indirect: By Flagship Pioneering Fund VI, L.P.)
Common Stock
Transactions
- Sale
Common Stock
2023-05-26$6.23/sh−9,330$58,093→ 1,425,334 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−102,245$649,481→ 11,174,664 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−13,127$83,385→ 1,434,664 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-24$6.57/sh−308,290$2,023,986→ 11,276,909 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-24$6.57/sh−39,580$259,851→ 1,447,791 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−72,670$452,480→ 11,101,994 total(indirect: By Flagship Ventures Fund V, L.P.)
Holdings
- 9,725,122(indirect: By Flagship Pioneering Fund VI, L.P.)
Common Stock
- 11,441,326(indirect: By LLC)
Common Stock
AFEYAN NOUBAR
10% Owner
Transactions
- Sale
Common Stock
2023-05-24$6.57/sh−39,580$259,851→ 1,447,791 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-24$6.57/sh−308,290$2,023,986→ 11,276,909 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−102,245$649,481→ 11,174,664 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-25$6.35/sh−13,127$83,385→ 1,434,664 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−72,670$452,480→ 11,101,994 total(indirect: By Flagship Ventures Fund V, L.P.) - Sale
Common Stock
2023-05-26$6.23/sh−9,330$58,093→ 1,425,334 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Holdings
- 11,441,326(indirect: By LLC)
Common Stock
- 9,725,122(indirect: By Flagship Pioneering Fund VI, L.P.)
Common Stock
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- [F3]Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.56, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]Represents shares held directly by Flagship VentureLabs V LLC. ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- [F7]Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Documents
Issuer
Sana Biotechnology, Inc.
CIK 0001770121
Entity typeother
Related Parties
1- filerCIK 0001222012
Filing Metadata
- Form type
- 4
- Filed
- May 25, 8:00 PM ET
- Accepted
- May 26, 8:00 PM ET
- Size
- 23.4 KB